SKINBIOTHERAPEUTICS PLC - Investor Presentation

SkinBioTherapeutics plc’s latest investor update outlines a period of significant corporate transition following governance issues that led to the restatement of FY25 accounts, while reaffirming confidence in the company’s long-term growth strategy and commercial assets. Management confirmed that £0.77m of previously accrued royalty revenue was removed after an investigation identified fabricated supporting documentation by the former CEO, with no other FY25 revenue issues or cash discrepancies found. Despite the disruption, first-half FY26 revenue increased to £2.17m (from £1.58m), driven by a full contribution from Biotech Solutions (BTS), resilient Dermatonics trading, and the first recognised royalty income from its Croda partnership, while maintaining gross margins of approximately 56% and reducing operating losses through improved cost discipline. The company’s growth strategy is now centred on expanding its core revenue-generating businesses, Dermatonics and BTS, carefully managing investment in the early-stage AxisBiotix consumer brand, and supporting long-term value creation through its SkinBiotix intellectual property licensing partnership with Croda. Management highlighted ongoing operational efficiencies, margin improvements, governance enhancements, and a pathway towards cash break-even supported by strict financial discipline and an expected minimum 12-month cash runway. With new leadership, strengthened corporate governance, and continued confidence in its commercial partnerships, SkinBioTherapeutics is focused on rebuilding investor confidence, executing its operational strategy, and delivering sustainable long-term shareholder value through growth in revenue, IP commercialisation, and operational performance.